{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:22:06Z","timestamp":1792606926644,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bladder cancer ranks as the 10th most common cancer worldwide, with deteriorating prognosis as the disease advances. While immune checkpoint inhibitors (ICIs) have shown promise in clinical therapy in both operable and advanced bladder cancer, identifying patients who will respond is challenging. Anoikis, a specialized form of cell death that occurs when cells detach from the extracellular matrix, is closely linked to tumor progression. Here, we aimed to explore the anoikis-based biomarkers for bladder cancer prognosis and immunotherapeutic decisions. Through consensus clustering, we categorized patients from the TCGA-BLCA cohort into two clusters based on anoikis-related genes (ARGs). Significant differences in survival outcome, clinical features, tumor immune environment (TIME), and potential ICIs response were observed between clusters. We then formulated a four-gene signature, termed \"Ascore\", to encapsulate this gene expression pattern. The Ascore was found to be closely associated with survival outcome and served as an independent prognosticator in both the TCGA-BLCA cohort and the IMvigor210 cohort. It also demonstrated superior predictive capacity (AUC\u2009=\u20090.717) for bladder cancer immunotherapy response compared to biomarkers like TMB and PD-L1. Finally, we evaluated Ascore\u2019s independent prognostic performance as a non-invasive biomarker in our clinical cohort (Gulou-Cohort1) using circulating tumor cells detection, achieving an\u00a0AUC of 0.803. Another clinical cohort (Gulou-Cohort2) consisted of 40 patients undergoing neoadjuvant anti-PD-1 treatment was also examined. Immunohistochemistry of Ascore in these patients revealed its correlation with the pathological response to bladder cancer immunotherapy (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004). Impressively, Ascore (AUC\u2009=\u20090.913) surpassed PD-L1 (AUC\u2009=\u20090.662) in forecasting immunotherapy response and indicated better net benefit. In conclusion, our study introduces Ascore as a novel, robust prognostic biomarker for bladder cancer, offering a new tool for enhancing immunotherapy decisions and contributing to the tailored treatment approaches in this field.\n                  <\/jats:p>","DOI":"10.1186\/s12943-024-01945-9","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T05:02:48Z","timestamp":1707541368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Tianlei","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"issue":"10364","key":"1945_CR1","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat E, Amin MB, Cathomas R, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400(10364):1712\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(22)01188-6.","journal-title":"Lancet"},{"issue":"1","key":"1945_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010.","journal-title":"Eur Urol"},{"issue":"1","key":"1945_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021;79(1):82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"Eur Urol"},{"issue":"7","key":"1945_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2.","journal-title":"Lancet Oncol"},{"issue":"22","key":"1945_CR5","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2034442.","journal-title":"N Engl J Med"},{"key":"1945_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.011","author":"JJ Meeks","year":"2023","unstructured":"Meeks JJ, Black PC, Galsky M, et al. Checkpoint Inhibitors in urothelial carcinoma-future directions and biomarker selection. Eur Urol. 2023. https:\/\/doi.org\/10.1016\/j.eururo.2023.05.011.","journal-title":"Eur Urol"},{"issue":"9","key":"1945_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1091\/mbc.4.9.953","volume":"4","author":"JE Meredith","year":"1993","unstructured":"Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell. 1993;4(9):953\u201361.","journal-title":"Mol Biol Cell"},{"key":"1945_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11970","author":"F Sattari Fard","year":"2022","unstructured":"Sattari Fard F, Jalilzadeh N, Mehdizadeh A, Sajjadian F, Velaei K. Understanding and targeting anoikis in metastasis for cancer therapies. Cell Biol Int. 2022. https:\/\/doi.org\/10.1002\/cbin.11970.","journal-title":"Cell Biol Int"},{"issue":"6","key":"1945_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1158\/0008-5472.CAN-19-0743","volume":"80","author":"BL Eckhardt","year":"2020","unstructured":"Eckhardt BL, Cao Y, Redfern AD, et al. Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. Cancer Res. 2020;80(6):1304\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0743.","journal-title":"Cancer Res"},{"issue":"19","key":"1945_CR10","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.3390\/cancers14194791","volume":"14","author":"J Wang","year":"2022","unstructured":"Wang J, Luo Z, Lin L, et al. Anoikis-associated lung cancer metastasis: mechanisms and therapies. Cancers (Basel). 2022;14(19):4791. https:\/\/doi.org\/10.3390\/cancers14194791.","journal-title":"Cancers (Basel)"},{"key":"1945_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2022.08.010","author":"M Bose","year":"2022","unstructured":"Bose M, Sanders A, De C, et al. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer. Transl Res. 2022. https:\/\/doi.org\/10.1016\/j.trsl.2022.08.010.","journal-title":"Transl Res"},{"key":"1945_CR12","doi-asserted-by":"publisher","first-page":"1136184","DOI":"10.3389\/fphar.2023.1136184","volume":"14","author":"L Qi","year":"2023","unstructured":"Qi L, Chen F, Wang L, Yang Z, Zhang W, Li ZH. Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcoma. Front Pharmacol. 2023;14:1136184. https:\/\/doi.org\/10.3389\/fphar.2023.1136184.","journal-title":"Front Pharmacol"},{"key":"1945_CR13","doi-asserted-by":"publisher","first-page":"1039465","DOI":"10.3389\/fgene.2022.1039465","volume":"13","author":"Z Chen","year":"2022","unstructured":"Chen Z, Liu X, Zhu Z, et al. A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma. Front Genet. 2022;13:1039465. https:\/\/doi.org\/10.3389\/fgene.2022.1039465.","journal-title":"Front Genet"},{"issue":"12","key":"1945_CR14","doi-asserted-by":"publisher","first-page":"10879","DOI":"10.1007\/s00432-023-04945-2","volume":"149","author":"L Yang","year":"2023","unstructured":"Yang L, Xu F. A novel anoikis-related risk model predicts prognosis in patients with colorectal cancer and responses to different immunotherapy strategies. J Cancer Res Clin Oncol. 2023;149(12):10879\u201392. https:\/\/doi.org\/10.1007\/s00432-023-04945-2.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"20","key":"1945_CR15","doi-asserted-by":"publisher","first-page":"17757","DOI":"10.1007\/s00432-023-05468-6","volume":"149","author":"Z Yue","year":"2023","unstructured":"Yue Z, Wang D, Li X. A promising anoikis-related prognostic signature predicts prognosis of skin cutaneous melanoma. J Cancer Res Clin Oncol. 2023;149(20):17757\u201370. https:\/\/doi.org\/10.1007\/s00432-023-05468-6.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1945_CR16","doi-asserted-by":"publisher","first-page":"939523","DOI":"10.3389\/fimmu.2022.939523","volume":"13","author":"Z Sun","year":"2022","unstructured":"Sun Z, Zhao Y, Wei Y, Ding X, Tan C, Wang C. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma. Front Immunol. 2022;13:939523. https:\/\/doi.org\/10.3389\/fimmu.2022.939523.","journal-title":"Front Immunol"},{"key":"1945_CR17","doi-asserted-by":"publisher","first-page":"1122570","DOI":"10.3389\/fimmu.2023.1122570","volume":"14","author":"Y Dong","year":"2023","unstructured":"Dong Y, Xu C, Su G, et al. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validation. Front Immunol. 2023;14:1122570. https:\/\/doi.org\/10.3389\/fimmu.2023.1122570.","journal-title":"Front Immunol"},{"key":"1945_CR18","doi-asserted-by":"publisher","first-page":"1055304","DOI":"10.3389\/fimmu.2022.1055304","volume":"13","author":"YY Zhang","year":"2022","unstructured":"Zhang YY, Li XW, Li XD, et al. Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy. Front Immunol. 2022;13:1055304. https:\/\/doi.org\/10.3389\/fimmu.2022.1055304.","journal-title":"Front Immunol"},{"issue":"7693","key":"1945_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"issue":"5","key":"1945_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2022;81(5):523\u201332. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.035.","journal-title":"Eur Urol"},{"issue":"12","key":"1945_CR21","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/btq170.","journal-title":"Bioinformatics"},{"issue":"7","key":"1945_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1945_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1\u201322.","journal-title":"J Stat Softw"},{"issue":"30","key":"1945_CR24","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues J-F, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381\u201397. https:\/\/doi.org\/10.1002\/sim.5958.","journal-title":"Stat Med"},{"issue":"1","key":"1945_CR25","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","volume":"11","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zhou L, Liu L, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11(1):5077. https:\/\/doi.org\/10.1038\/s41467-020-18916-5.","journal-title":"Nat Commun"},{"issue":"13","key":"1945_CR26","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-3587.e29. https:\/\/doi.org\/10.1016\/j.cell.2021.04.048.","journal-title":"Cell"},{"issue":"3","key":"1945_CR27","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.","journal-title":"Innovation (Camb)"},{"key":"1945_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. https:\/\/doi.org\/10.1186\/1471-2105-14-7.","journal-title":"BMC Bioinformatics"},{"key":"1945_CR29","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"issue":"10","key":"1945_CR30","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0136-1.","journal-title":"Nat Med"},{"issue":"11","key":"1945_CR31","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356. https:\/\/doi.org\/10.1101\/gr.239244.118.","journal-title":"Genome Res"},{"issue":"11","key":"1945_CR32","doi-asserted-by":"publisher","first-page":"100785","DOI":"10.1016\/j.xcrm.2022.100785","volume":"3","author":"J Hu","year":"2022","unstructured":"Hu J, Chen J, Ou Z, et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study. Cell Rep Med. 2022;3(11):100785. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100785.","journal-title":"Cell Rep Med"},{"issue":"1","key":"1945_CR33","doi-asserted-by":"publisher","first-page":"1738798","DOI":"10.1080\/2162402X.2020.1738798","volume":"9","author":"S Bergmann","year":"2020","unstructured":"Bergmann S, Coym A, Ott L, et al. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Oncoimmunology. 2020;9(1):1738798. https:\/\/doi.org\/10.1080\/2162402X.2020.1738798.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1945_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/pai.0000000000000163","volume":"23","author":"EE Torlakovic","year":"2015","unstructured":"Torlakovic EE, Nielsen S, Francis G, et al. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol. 2015;23(1):1\u201318. https:\/\/doi.org\/10.1097\/pai.0000000000000163.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"1945_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/pai.0000000000000069","volume":"22","author":"EE Torlakovic","year":"2014","unstructured":"Torlakovic EE, Francis G, Garratt J, et al. Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. Appl Immunohistochem Mol Morphol. 2014;22(4):241\u201352. https:\/\/doi.org\/10.1097\/pai.0000000000000069.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"1945_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341\u201352. https:\/\/doi.org\/10.1038\/s41580-020-0237-9.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"1945_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M. NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309\u201324. https:\/\/doi.org\/10.1038\/nri.2017.142.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"1945_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","volume":"19","author":"Y-C Lee","year":"2022","unstructured":"Lee Y-C, Lam H-M, Rosser C, Theodorescu D, Parks WC, Chan KS. The dynamic roles of the bladder tumour microenvironment. Nat Rev Urol. 2022;19(9):515\u201333. https:\/\/doi.org\/10.1038\/s41585-022-00608-y.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"1945_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"issue":"3","key":"1945_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/emm.2005.27","volume":"37","author":"E-M Choi","year":"2005","unstructured":"Choi E-M, Kwak S-J, Kim Y-M, et al. COX-2 inhibits anoikis by activation of the PI-3K\/Akt pathway in human bladder cancer cells. Exp Mol Med. 2005;37(3):199\u2013203.","journal-title":"Exp Mol Med"},{"issue":"1","key":"1945_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12885-019-5426-6","volume":"19","author":"S Lv","year":"2019","unstructured":"Lv S, Wang W, Wang H, Zhu Y, Lei C. PPAR\u03b3 activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer. 2019;19(1):204. https:\/\/doi.org\/10.1186\/s12885-019-5426-6.","journal-title":"BMC Cancer"},{"issue":"1","key":"1945_CR42","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss M, Donia M, Harbst K, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8(1):1738. https:\/\/doi.org\/10.1038\/s41467-017-01460-0.","journal-title":"Nat Commun"},{"key":"1945_CR43","doi-asserted-by":"publisher","first-page":"104237","DOI":"10.1016\/j.ebiom.2022.104237","volume":"83","author":"Z Deng","year":"2022","unstructured":"Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022;83:104237. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104237.","journal-title":"EBioMedicine"},{"issue":"11","key":"1945_CR44","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1200\/jco.2013.51.7417","volume":"32","author":"A Goldkorn","year":"2014","unstructured":"Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32(11):1136\u201342. https:\/\/doi.org\/10.1200\/jco.2013.51.7417.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1945_CR45","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.7150\/jca.35308","volume":"11","author":"PP Wang","year":"2020","unstructured":"Wang PP, Liu SH, Chen CT, et al. Circulating tumor cells as a new predictive and prognostic factor in patients with small cell lung cancer. J Cancer. 2020;11(8):2113\u201322. https:\/\/doi.org\/10.7150\/jca.35308.","journal-title":"J Cancer"},{"issue":"1","key":"1945_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13058-018-1030-y","volume":"20","author":"H Zhang","year":"2018","unstructured":"Zhang H, Fredericks T, Xiong G, et al. Membrane associated collagen XIII promotes cancer metastasis and enhances anoikis resistance. Breast Cancer Res. 2018;20(1):116. https:\/\/doi.org\/10.1186\/s13058-018-1030-y.","journal-title":"Breast Cancer Res"},{"issue":"35","key":"1945_CR47","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1038\/onc.2011.89","volume":"30","author":"JV Burnier","year":"2011","unstructured":"Burnier JV, Wang N, Michel RP, et al. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene. 2011;30(35):3766\u201383. https:\/\/doi.org\/10.1038\/onc.2011.89.","journal-title":"Oncogene"},{"issue":"10","key":"1945_CR48","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","volume":"16","author":"AK Schneider","year":"2019","unstructured":"Schneider AK, Chevalier MF, Derr\u00e9 L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol. 2019;16(10):613\u201330. https:\/\/doi.org\/10.1038\/s41585-019-0226-y.","journal-title":"Nat Rev Urol"},{"issue":"13","key":"1945_CR49","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1002\/cam4.3955","volume":"10","author":"Y Zuo","year":"2021","unstructured":"Zuo Y, Xu X, Chen M, Qi L. The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo. Cancer Med. 2021;10(13):4437\u201350. https:\/\/doi.org\/10.1002\/cam4.3955.","journal-title":"Cancer Med"},{"issue":"11","key":"1945_CR50","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3390\/cancers11111620","volume":"11","author":"MKB Ahmat Amin","year":"2019","unstructured":"Ahmat Amin MKB, Shimizu A, Ogita H. The pivotal roles of the epithelial membrane protein family in cancer invasiveness and metastasis. Cancers (Basel). 2019;11(11):1620. https:\/\/doi.org\/10.3390\/cancers11111620.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1945_CR51","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3892\/ol.2020.11841","volume":"20","author":"B Lin","year":"2020","unstructured":"Lin B, Zhang T, Ye X, Yang H. High expression of EMP1 predicts a poor prognosis and correlates with immune infiltrates in bladder urothelial carcinoma. Oncol Lett. 2020;20(3):2840\u201354. https:\/\/doi.org\/10.3892\/ol.2020.11841.","journal-title":"Oncol Lett"},{"key":"1945_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2022.06.247","volume":"189","author":"S Liu","year":"2022","unstructured":"Liu S, Shi J, Wang L, et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free Radic Biol Med. 2022;189:42\u201357. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.06.247.","journal-title":"Free Radic Biol Med"},{"key":"1945_CR53","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.imlet.2019.11.005","volume":"217","author":"E Sparrow","year":"2020","unstructured":"Sparrow E, Bodman-Smith MD. Granulysin: The attractive side of a natural born killer. Immunol Lett. 2020;217:126\u201332. https:\/\/doi.org\/10.1016\/j.imlet.2019.11.005.","journal-title":"Immunol Lett"},{"issue":"11","key":"1945_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrm2039","volume":"7","author":"NK Tonks","year":"2006","unstructured":"Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7(11):833\u201346.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1945_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.201303698","volume":"7","author":"SA Joosse","year":"2015","unstructured":"Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7:1\u201311. https:\/\/doi.org\/10.15252\/emmm.201303698.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"1945_CR56","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1015312119693","volume":"7","author":"J Grossmann","year":"2002","unstructured":"Grossmann J. Molecular mechanisms of \u201cdetachment-induced apoptosis\u2013Anoikis.\u201d Apoptosis. 2002;7(3):247\u201360.","journal-title":"Apoptosis"},{"issue":"13","key":"1945_CR57","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.7150\/jca.42663","volume":"11","author":"T Peng","year":"2020","unstructured":"Peng T, Wang G, Cheng S, et al. The role and function of PPAR\u03b3 in bladder cancer. J Cancer. 2020;11(13):3965\u201375. https:\/\/doi.org\/10.7150\/jca.42663.","journal-title":"J Cancer"},{"key":"1945_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01113-z","author":"A Singh","year":"2023","unstructured":"Singh A, Osbourne AS, Koshkin VS. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer. Curr Treat Options Oncol. 2023. https:\/\/doi.org\/10.1007\/s11864-023-01113-z.","journal-title":"Curr Treat Options Oncol"},{"issue":"17","key":"1945_CR59","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1158\/1078-0432.Ccr-16-3065","volume":"23","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Yarchoan M, Hansen AR, et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin Cancer Res. 2017;23(17):4959\u201369. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3065.","journal-title":"Clin Cancer Res"},{"key":"1945_CR60","doi-asserted-by":"publisher","unstructured":"Saal J, Gr\u00fcnwald V, Bald T, et al. On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. Eur Urol Oncol.\u00a0https:\/\/doi.org\/10.1016\/j.euo.2023.11.005. Published online November 22 2023.","DOI":"10.1016\/j.euo.2023.11.005"},{"issue":"11","key":"1945_CR61","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/jco.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850\u20135. https:\/\/doi.org\/10.1200\/jco.2009.25.4599.","journal-title":"J Clin Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-01945-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-024-01945-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-024-01945-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T05:04:12Z","timestamp":1707541452000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-024-01945-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1945"],"URL":"https:\/\/doi.org\/10.1186\/s12943-024-01945-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by\u00a0the Ethics Committee of Drum Tower Hospital (ethical number: 2022\u2013493-01). All methods were performed in accordance with relevant guidelines and regulations. Informed consents were obtained from each participant or their immediate families.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}